November 13, 2008

Ranbaxy-Daiichi Deal Dissected 

Dear All,

 

With the completion of acquisition of 63.92% equity stake in Ranbaxy Laboratories Limited (“Ranbaxy”), India's largest pharmaceutical company, by Japanese pharma major Daiichi Sankyo Co., Ltd. (“Daiichi”), on November 7, 2008, it would be interesting to analyze the key legal and tax issues that arose from the beginning till the completion of this landmark deal.

 

For a detailed analysis of the legal and tax issues, please click here for the document.

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative.

 

 


 Team M&A
 Ruchi Biyani / R. Vaidhyanadhan Iyer / Nishchal Joshipura
You can direct your queries or comments to Team M&A
 

Welcome to connect with us at interesting conferences, seminars and events (more...

  VIDEO
Vyapak Desai on FII, FDI norms
Kartik Ganapathy on Ranbaxy Daiichi deal
Nishith Desai on Vodafone Controversy
Siddharth Shah on P Notes
 
  ARTICLES, HOTLINES & RESEARCH REPORTS
SEBI goes the distance in easing takeover regulations, The Economic Times, Ruchir Sinha & Nishchal Joshipura, November 11, 2008
Is it time to bid adieu to ‘poison pills’? The Economic Times, R Vaidhyanadhan Iyer & Nishchal Joshipura, May 27, 2008
Amendments To Takeover Code – Oversight Or Intended?, November 7, 2008 
Mergers & Acquisitions in India  
Venture Capital at Crossroads
 
  SUBSCRIPTION

We update our clients by sending various hotlines. You can subscribe to one / more hotlines also. You can email us for registering yourself for any of the hotlines given below.

Corpsec Hotline
Tax Hotline
HR Hotline
iCe Hotline
Annual Budget
FII Hotline
Pharma Update
Infra Update
IP Update
Dispute Resolution Hotline


Unsubscribe
Feedback





Disclaimer: The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This hotline provides general information existing at the time of preparation. The hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any  loss arising to any person acting or refraining from acting as a result of any material contained in this hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This hotline does not substitute the need to refer to the original pronouncements. 

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.